Quantinno Capital Management LP Buys 53,849 Shares of Sanofi $SNY

Quantinno Capital Management LP raised its stake in Sanofi (NASDAQ:SNY) by 24.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 271,089 shares of the company’s stock after buying an additional 53,849 shares during the quarter. Quantinno Capital Management LP’s holdings in Sanofi were worth $13,061,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of SNY. Flagship Harbor Advisors LLC acquired a new stake in shares of Sanofi in the 4th quarter valued at approximately $25,000. Physician Wealth Advisors Inc. grew its holdings in Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after purchasing an additional 379 shares during the period. Leonteq Securities AG increased its stake in Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after purchasing an additional 297 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in Sanofi in the third quarter worth $29,000. Finally, Palisade Asset Management LLC bought a new position in shares of Sanofi during the third quarter worth $30,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on SNY. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Morgan Stanley set a $49.00 price target on Sanofi in a research report on Wednesday, July 8th. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Monday, April 20th. Finally, Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Sanofi currently has an average rating of “Hold” and an average target price of $49.50.

Sanofi Stock Performance

SNY opened at $42.95 on Tuesday. The company has a market capitalization of $104.13 billion, a price-to-earnings ratio of 22.49, a P/E/G ratio of 1.15 and a beta of 0.35. The business’s 50-day moving average price is $43.41 and its two-hundred day moving average price is $45.16. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.